Pharmacy world & science : PWS · 2009
Severe ifosfamide-induced neurotoxicity: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ramos Linares Sara, Breña Atienza Joaquín, Cháfer Rudilla Matilde, Ríos Rull Pablo, Cabello Rodríguez Ana, Merino Alonso Javier
Аннотация
INTRODUCTION: Ifosfamide is an alkylating agent used in the treatment of several neoplasias. Ifosfamide metabolites accumulation can produce neurotoxicity, which sometimes manifests as a severe clinical picture.
CASE DESCRIPTION: We describe the case of a male with a mixed cellularity subtype classical Hodgkin's lymphoma, treated with ifosfamide after other chemotherapy drugs failure. After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy.
DISCUSSION: Among the risk factors described in the literature, our patient had previously received cisplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion. The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used.
CONCLUSION: This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.
CASE DESCRIPTION: We describe the case of a male with a mixed cellularity subtype classical Hodgkin's lymphoma, treated with ifosfamide after other chemotherapy drugs failure. After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy.
DISCUSSION: Among the risk factors described in the literature, our patient had previously received cisplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion. The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used.
CONCLUSION: This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.